The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations

American Journal of Cardiology

Volumn 90, Issue 2, 2002, Pages 139-143

  Sacks, Frank M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; BEZAFIBRATE; CHOLESTEROL; CHYLOMICRON; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY RISK; DIET; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; EXERCISE; GENE EXPRESSION; GENE THERAPY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID METABOLISM; LIVER; META ANALYSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0037099364     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02436-0     Document Type: Note

References (31)

1. HDL cholesterol and cardiovascular disease: Four prospective American studies
2. HDL cholesterol as a predictor of coronary heart disease risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport
3. International symposium on basic aspects of HDL metabolism and disease prevention
4. Regression of atherosclerotic lesions by HDL plasma fraction in the cholesterol-fed rabbit
5. Somatic gene transfer of human apoA-1 inhibits atherosclerosis progression in mouse models
6. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans
7. Normal HDL inhibits three steps in the formation of mildly oxidzied LDL
8. Very low density lipoproteins, apolipoproteins B, CIII, and E and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) Trial
9. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
10. Declining serum total cholesterol levels amoung US adults: The National Health and Nutrition Examination Surveys
11. Range of serum cholesterol in the population developing coronary artery disease
12. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events trial
13. Lipoprotein changes and reduction in the incidence of major coronary events in the Scandinavian Simvastatin Survival Study
14. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors
15. Relation between baseline and on treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study
16. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial
17. High monounsaturated fat diets for patients with diabetes mellitus: A meta-analysis
18. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia
19. Metabolic basis of HDL and apolipoprotein A-I increase by HMG CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
20. The role of fibric acids in atherosclerosis
21. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
22. Mechanism of action of niacin on lipoprotein metabolism
23. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
24. Gemfibrozil for the secondary prevention of coronary heart disease in men with low HDL-cholesterol
25. Relation of gemfibrozil treatment and lipid levels with major coronary events
26. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
27. Effect of fenofibrate on progression of conary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
28. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: Experience from the Helsinki Heart Study
29. Clofibrate and niacin in coronary heart disease
30. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study
31. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)